BD111 gene therapy for herpes simplex virus eye infection
Part of Eyes & vision, Infections clinical trials.
This trial tests a new gene therapy called BD111 for people with a herpes simplex virus infection in the cornea (the clear front part of the eye). It aims to see if the treatment is safe and can help clear the virus, possibly improving vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with herpes simplex virus infection in the cornea (stromal keratitis).
- You have a positive tear test for the virus.
- You have not used antiviral drugs or steroids in your eye in the last 48 hours.
- You do not have other eye diseases like severe dry eye, glaucoma, or a history of corneal transplant.
- You are willing to use effective birth control during the trial and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether injecting an anti-VEGF medication directly into the clear part of your eye (cornea) can safely reduce abnormal blood vessels caused by a herpes virus eye infection. If you have HSV keratitis with new vessel growth and haven't had prior anti-VEGF treatment or corneal surgery, this trial may be an option for you.
This trial tests a new gene therapy to treat a type of corneal dystrophy caused by a faulty gene. It aims to improve symptoms and slow the disease's progression.
This study tests a new gene therapy called LX111 for diabetic macular edema (DME) that has not improved enough with previous injections. It aims to see if a single treatment can reduce swelling and improve vision.
This trial tests an investigational gene therapy called ZVS101e for people with Bietti's crystalline dystrophy (BCD), a rare inherited eye disease. It aims to see if the treatment can help slow vision loss or improve vision.
This trial offers compassionate use of the gene therapy ZVS101e for people with Bietti crystalline dystrophy (BCD) who were in the control group of an earlier study. It aims to give extended treatment access to those who didn't receive the experimental therapy before.
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
Hear when a new Herpes Simplex Virus Type I Stromal Keratitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.